Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Xconomy: 89bio Joins Nash Chase With A Teva Drug And $65M In Funding
Venture Capital

Xconomy: 89bio Joins Nash Chase With A Teva Drug And $65M In Funding

by xconomy.com posted 10months ago 45 views
The competition to develop a treatment for nonalcoholic steatohepatitis, a serious liver disorder, has another player. 89Bio launched Thursday with $65 million in financing and a lead compound originally developed by Teva Pharmaceutical. San Francisco-based 89Bio says that it has acquired a pipeline of biologic and small molecule drug candidates from Teva (NYSE: TEVA). The […]

In this article